-transparent.png){kind=logo}
The immunoglobulin (Ig) variable region (V) genes expressed by IgM chronic lymphocytic leukemia (CLL) B cells display little or no somatic mutations. However, preliminary findings have shown that Ig V genes of IgA and IgG CLLs may be somatically mutated, suggesting that isotype-switched CLLs may represent a "subtype" of the disease. To investigate the degree and nature of somatic mutations and the role of antigen (Ag) in the clonal selection and expansion of isotype-switched CLLs, and to determine whether specific oncogene or tumor suppressor gene mutations are associated with isotype-switched CLLs, we analyzed the expressed Ig VH gene, bcl-1 and bcl-2 proto-oncogene, and p53 tumor suppressor gene configurations of 3 IgA-, 1 IgG-, and 1 IgA/ IgG-expressing CLLs. These isotype-switched CLL B cells expressed surface HLA-DR, CD19, CD23, and CD5, and displayed no alterations of the bcl-1 and bcl-2 oncogenes and the p53 tumor-suppressor gene. The cDNA VH-D-JH gene sequence was joined with that of the C alpha gene in the B cells of the three IgA CLLs, and with that of the C gamma gene in the IgG CLL B cells. In the IgA/IgG-coexpressing CLL B cells, identical VH-D-JH cDNA sequences were spliced to either C alpha or C gamma genes. In all five CLLs, the pattern of C mu DNA probe hybridization to the digested genomic DNAs was consistent with deletion of the C mu exon from the rearranged Ig gene locus, suggesting that these CLL B cells had undergone DNA switch recombination. In one IgA CLL, the expressed VH gene was unmutated. In all other class-switched CLLs, the Ig VH segment gene was mutated, but the point mutations were not associated with intraclonal diversification. In one IgA and in the IgA/IgG-coexpressing CLL, the nature and distribution of the mutations were consistent with Ag selection. These findings suggest that IgA- and/or IgG-expressing CLLs represent, in their VH gene structure, transformants of B cells at different stages of ontogeny. They also suggest that Ag may play a role in the clonal selection of some of these isotype-switched leukemic cells, but bcl-1 and bcl-2 oncogene rearrangements and p53 tumor suppressor gene mutation are not associated with the pathogenesis of isotype-switched CLLs.
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
January 1979,
Advances in experimental medicine and biology,
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
November 1992,
Blood,
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
September 1991,
American journal of hematology,
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
September 2008,
Genes, chromosomes & cancer,
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
January 1994,
Autoimmunity,
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
January 1999,
Clinical immunology (Orlando, Fla.),
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
March 1977,
Cancer,
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
September 1994,
Leukemia,
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
March 2008,
Haematologica,
A Matolcsy, and
P Casali, and
R G Nádor, and
Y F Liu, and
D M Knowles
January 1998,
Annals of hematology,
